Nephrolithiasis-associated bone disease: pathogenesis and treatment options. - Wikidata - wikimedia - TriplyDB

Nephrolithiasis-associated bone disease: pathogenesis and treatment options.

Nephrolithiasis-associated bone disease: pathogenesis and treatment options.

http://www.wikidata.org/entity/Q34936324

about

Dietary interventions for preventing complications in idiopathic hypercalciuria New insights into the pathogenesis of renal calculi Is nephrolithiasis an unrecognized extra-articular manifestation in ankylosing spondylitis? A prospective population-based Swedish national cohort study with matched general population comparator subjects The Effect of Glycemic Status on Kidney Stone Disease in Patients with Prediabetes.Mucin-1 Increases Renal TRPV5 Activity In Vitro, and Urinary Level Associates with Calcium Nephrolithiasis in Patients Expression of fibroblast growth factor 23, vitamin D receptor, and sclerostin in bone tissue from hypercalciuric stone formers.Reduced renal calcium excretion in the absence of sclerostin expression: evidence for a novel calcium-regulating bone kidney axis.Clinical review. Kidney stones 2012: pathogenesis, diagnosis, and management.Bone mineral density status in urolithiasis patients with vitamin D inadequacy followed at a tertiary stone centre.Correlation of serum and ionized calcium in patients with calcium nephrolithiasis Incidence of osteoporosis in patients with urolithiasis.The importance of urinary calcium in postmenopausal women with osteoporotic fracture.Modeling hypercalciuria in the genetic hypercalciuric stone-forming rat Deletion of the Cl-/HCO3- exchanger pendrin downregulates calcium-absorbing proteins in the kidney and causes calcium wasting.Association between serum vitamin D levels and the risk of kidney stone: evidence from a meta-analysis.Prevalence of osteoporosis in the Italian population and main risk factors: results of BoneTour Campaign The relation between bone and stone formation Metabolic diagnosis and medical prevention of calcium nephrolithiasis and its systemic manifestations: a consensus statement.Idiopathic hypercalciuria and bone health.Calcium renal lithiasis: metabolic diagnosis and medical treatment.Nephrolithiasis, bone mineral density, osteoporosis, and fractures: a systematic review and comparative meta-analysis.Longitudinal study of bone mineral density in children with idiopathic hypercalciuria.Stones, bones, and cardiovascular groans.Low Bone Density and Bisphosphonate Use and the Risk of Kidney Stones.Role of FGF23 in Pediatric Hypercalciuria.Bone remodeling markers as lithogenic risk factors in patients with osteopenia-osteoporosis.Osteopenia/osteoporosis in patients with calcium nephrolithiasis.Association between low bone mass and the serum RANKL and OPG in patients with nephrolithiasis.Hyponatremia and the risk of kidney stones: A matched case-control study in a large U.S. health system

P2860

Q24200428-F14BB079-C41C-4AC1-A5CE-B569990B11BE Q27026371-9E0D1B6A-82AF-45B3-BCFB-BE5915688BE9 Q28545171-A7535301-EC5D-4BD3-83FF-1F44E7F6F9D5 Q30384110-FFE12523-7604-4F9F-A5CD-444223936DF4 Q30386353-88D9FD5E-49F9-4221-A4A6-022C753C560D Q33835734-1FB0CFA7-ECF2-4670-B231-09CCB1963A18 Q34260123-647BBA0B-86C0-40D6-9D94-A700814BE202 Q34265048-B349ED2E-75A0-48BA-89B1-8193BB1A1990 Q34435990-835CE7E8-6492-4807-A845-3C74C217016B Q34557058-ADE4E2C2-FE65-44DD-A73E-CA87E168DA91 Q34725450-B9473A87-4C67-4208-93DE-E8B53DC80F80 Q35683357-A4670B96-481D-458D-84FB-BC854EBE5591 Q35830544-CB97D518-BD99-411E-968E-3C69D990063C Q35861449-5BC080AB-6D20-4314-ACD6-046D105B4DD6 Q35974644-0A15328A-24A6-4A94-A234-8F5D887865EA Q36136311-DB668B1C-1AFE-49E4-A01E-613F49331A1A Q36763774-53E93AB8-EFC2-4A23-A3AD-33AC89EFC21C Q37366264-4D1DE34C-E14A-4066-BF4E-A1C1BCB0D746 Q38051251-2431D16D-B0E4-4375-930B-3C046315D5E5 Q38094025-EE314ED6-F061-437F-9B2E-D7FE25C629E2 Q38854569-80298380-44A4-4954-9F44-6D65E5659962 Q39726042-584B0B8D-FF70-4C96-8B0C-2AA6E5024180 Q43011420-7E2704DE-FE85-4577-AD09-29899AD2EADD Q47743274-3F9AD65D-222B-4822-9A36-D1852653C12C Q49865594-751CB225-D341-4951-9A01-48CA96E48DF7 Q51282308-2CEC61FA-AC62-46EE-B5E0-A195655385FC Q51352825-212B3899-5479-41AF-8F3D-29CF06950C32 Q55714490-FE646CDA-2A35-428E-9076-86165747AFA3 Q58707401-05F8A9C5-7E74-4233-9F74-5614E95150BA

P2860

Nephrolithiasis-associated bone disease: pathogenesis and treatment options.

http://www.wikidata.org/entity/Q34936324

description

2010 nî lūn-bûn

@nan

2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Nephrolithiasis-associated bone disease: pathogenesis and treatment options.

@ast

Nephrolithiasis-associated bone disease: pathogenesis and treatment options.

@en

Nephrolithiasis-associated bone disease: pathogenesis and treatment options.

@nl

type

label

Nephrolithiasis-associated bone disease: pathogenesis and treatment options.

@ast

Nephrolithiasis-associated bone disease: pathogenesis and treatment options.

@en

Nephrolithiasis-associated bone disease: pathogenesis and treatment options.

@nl

prefLabel

Nephrolithiasis-associated bone disease: pathogenesis and treatment options.

@ast

Nephrolithiasis-associated bone disease: pathogenesis and treatment options.

@en

Nephrolithiasis-associated bone disease: pathogenesis and treatment options.

@nl

P1433

Q34936324-FF1A6E1A-B892-465C-BBDA-2FDF6B62FF7B

P1476

Q34936324-03C7B449-7999-4060-9B1D-991FFF971FF1

P2093

Q34936324-09ED980F-C8F6-4500-84D8-DB72A7149346

Q34936324-39C01D81-4A6A-410F-8B50-05503D7A4DFB

Q34936324-8B202400-93CF-4756-8D14-4E6C829C974A

Q34936324-BBB5FB40-25DA-4BFD-A808-A4662825A488

Q34936324-F5FC3411-5075-4068-B136-174E6A3F0DCD

P2860

Q34936324-0764F52A-6C3E-4434-B8E4-3C10E5BD6EC3

Q34936324-09552D77-7873-40ED-880F-0BF710A30557

Q34936324-0E421BFF-A2A0-43FD-9C6B-19487181B4F8

Q34936324-10CD7A1A-AC75-4C26-AA99-D6C03854372D

Q34936324-11AF2FB1-4C4A-4373-8B4D-8EA6ADD248E1

Q34936324-12E9BD1C-ADA1-4A1A-9A41-B81EBC47725C

Q34936324-13F9EF18-B758-4521-8556-1CEDF05D11EC

Q34936324-14D88437-9633-4483-8DFF-B4110379DBA2

Q34936324-18FA04E6-A5C5-4CE4-9B4A-51BB2236730E

Q34936324-191D76FA-8EEC-4B08-95AD-B8E58794BB38

P2888

Q34936324-BBF60A0A-05F4-4CBC-AD0D-C2D6378D22FA

P304

Q34936324-7B66D6B3-15C1-4665-A16F-7EA00666061E

P31

Q34936324-6A67FD58-1265-4C2D-A713-B7F28B1ABA07

Q34936324-8cff1ef2-49dd-49a6-9d8e-1bca257e0426

P356

Q34936324-575E5196-A954-4142-8EEC-1246A951A7F9

P407

Q34936324-D1EE1C95-2DAD-4BA3-8A1E-3DA9F1B83831

P433

Q34936324-084F5FC4-6205-4F60-846E-CEC63FB9C173

P478

Q34936324-880159E7-FC3B-477A-9313-FEBBDAF7B50D

P577

Q34936324-64848AEC-5CF1-4746-A82A-D3FB92B6CF3A

P5875

Q34936324-711FD4D0-22B4-45F1-AC46-85905E96284D

P6179

Q34936324-EC802A7E-FA75-4C03-959E-4F5FB58EA6CB

P698

Q34936324-0436A8ED-9495-4441-840A-632F6C97A95E

P932

Q34936324-539CF717-722F-4315-A560-7BF3B4E960D0

P356

P1433

Kidney International

P1476

Nephrolithiasis-associated bone disease: pathogenesis and treatment options.

@en

P2093

Andreas Pasch

http://www.w3.org/2001/XMLSchema#string

Khashayar Sakhaee

http://www.w3.org/2001/XMLSchema#string

Naim M Maalouf

http://www.w3.org/2001/XMLSchema#string

Orson W Moe

http://www.w3.org/2001/XMLSchema#string

Rajiv Kumar

http://www.w3.org/2001/XMLSchema#string

P2860

A common molecular basis for three inherited kidney stone diseases

Dent Disease with mutations in OCRL1

Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis

Treatment with potassium bicarbonate lowers calcium excretion and bone resorption in older men and women

Sequence variants in the CLDN14 gene associate with kidney stones and bone mineral density

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

Indapamide, a thiazide-like diuretic, decreases bone resorption in vitro.

Bone mass loss in calcium stone disease: focus on hypercalciuria and metabolic factors.

Acidosis inhibits osteoblastic and stimulates osteoclastic activity in vitro.

Bone disease in medullary sponge kidney and effect of potassium citrate treatment.

P2888

P304

393-403

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/KI.2010.473

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

79

http://www.w3.org/2001/XMLSchema#string

P577

2010-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49651426

http://www.w3.org/2001/XMLSchema#string

P6179

1006327895

http://www.w3.org/2001/XMLSchema#string

P698

21124301

http://www.w3.org/2001/XMLSchema#string

P932

3088506

http://www.w3.org/2001/XMLSchema#string